gestoden/etinilestradiol sandoz 0,075/0,030 mg tablete
sandoz d.d. - etinilestradiol, gestoden - tableta - etinilestradiol 0,03 mg / 1 tableta; gestoden 0,075 mg / 1 tableta - gestoden in etinilestradiol
gestoden/etinilestradiol sandoz 0,075/0,020 mg tablete
sandoz d.d. - etinilestradiol; gestoden - tableta - etinilestradiol 0,02 mg / 1 tableta gestoden0,075 mg / 1 tableta; gestoden 0,075 mg / 1 tableta - gestoden in etinilestradiol
gestoden/etinilestradiol sandoz 0,075/0,030 mg tablete
sandoz d.d. - etinilestradiol; gestoden - tableta - etinilestradiol 0,03 mg / 1 tableta gestoden0,075 mg / 1 tableta; gestoden 0,075 mg / 1 tableta - gestoden in etinilestradiol
etinilestradiol/drospirenon sandoz 0,02 mg/3 mg filmsko obložene tablete
sandoz d.d. - drospirenon; etinilestradiol - filmsko obložena tableta - drospirenon 3 mg / 1 tableta etinilestradiol0,02 mg / 1 tableta; etinilestradiol 0,02 mg / 1 tableta - drospirenon in etinilestradiol
etonogestrel/etinilestradiol mithra pharmaceuticals 0,120 mg/0,015 mg na 24 ur vaginalni dostavni sistem
etinilestradiol; etinilestradiol; etonogestrel - vaginalni dostavni sistem - etinilestradiol 2,7 mg / 1 sistem etinilestradiol2,7 mg / 1 sistem etonogestrel11,7 mg / 1 sistem; etinilestradiol 2,7 mg / 1 sistem etonogestrel11,7 mg / 1 sistem; etonogestrel 11,7 mg / 1 sistem - vaginalni obroček s progestogenom in estrogenom
colestyramin-ratiopharm 4 g prašek za peroralno suspenzijo
sanolabor, d.d. - holestiramin - prašek za peroralno suspenzijo - holestiramin 4 g / 1 g - holestiramin
resincolestiramina 4 g prašek za peroralno suspenzijo
lenis d.o.o. - holestiramin - prašek za peroralno suspenzijo - holestiramin 4 g / 1 vreča - holestiramin
lonsurf
les laboratoires servier - trifluridine, tipiracil hidroklorid - kolorektalne neoplazme - antineoplastična sredstva - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.
onivyde pegylated liposomal (previously known as onivyde)
les laboratoires servier - irinotecan anhydrous free-base - pankreatične neoplazme - antineoplastična sredstva - zdravljenje metastatskega adenokarcinoma trebušne slinavke, v kombinaciji z 5 flúorouracíl (5-fu) in leucovorin (lv), pri odraslih bolnikih, ki so napredovali po gemcitabin na zdravljenje.
pixuvri
les laboratoires servier - pixantrone dimaleate - limfom, non-hodgkin - antineoplastična sredstva - zdravilo pixuvri je indicirano kot monoterapija za zdravljenje odraslih bolnikov z multiplo relapsnimi ali neodzivnimi agresivnimi limfomi brez hodgkinov b celic (nhl). prednost piksantona pri bolnikih, ki se uporabljajo kot pete ali večje kemoterapije pri bolnikih, ki so odporni na zadnjo terapijo.